Daiichi Sankyo Co Ltd ADR (DSNKY)

32.63 -0.44 (-1.33%)
Close USD Disclaimer
32.61 -0.02 (-0.07%)

Daiichi Sankyo Co Ltd ADR Company Profile

Equity Type
Daiichi Sankyo Company, Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; and ferric carboxymaltose injection for treating anemia. It also provides edoxaban, an oral, once-daily, direct factor Xa inhibitor; esaxerenone and olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastases from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Contact Information
Tokyo,103-8426 Japan
81 3 6225 1111
Top Executives
Takashi Fukuoka 62 2022 Senior Executive Officer, Global Head of Corporate Strategy, Chief Strategy Officer & Director
Ryoichi Watanabe 65 2019 Member of Audit & Supervisory Board
Shoji Hirashima 62 2017 Senior Executive Officer, Head of Japan Business Unit & Director
Yukiko Imazu 55 2018 Outside Independent Audit & Supervisory Board Member
Kenji Sato 60 2019 Member of Audit & Supervisory Board
Hiroyuki Okuzawa 61 2018 President, COO & Representative Director
Masahiko Ohtsuki 64 2014 Senior Executive Officer, Head of Global DX, Chief Digital Transformation Officer & Director
Masako Watanabe 61 2021 Outside Audit & Supervisory Board Member
Yasuhiro Komatsu 66 2022 Independent Outside Director
Sunao Manabe 69 2009 Group CEO & Executive Chairperson
Mitsuhiro Matsumoto 62 2022 Outside Independent Audit & Supervisory Board Member
Sawako Nohara 65 2019 Independent Outside Director
Kazuaki Kama 75 2019 Independent Outside Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles